AKT1 and urinary bladder carcinoma: In the present study, therefore, we used in vitro and in vivo experiments to explore the potential of SIP-SII to overcome resistance to the FGFR inhibitor AZD4547 in bladder cancer cells carrying active FGFR and hyperactive AKT mutations.